Switch theme
Sign up to access all valuation multiples
Biofarm SA is a company engaged in production and marketing in the pharmaceutical sector. It is involved in the manufacture and wholesale of over-the-counter drugs, prescription medications, and dietary supplements. The firm's product portfolio includes pharmaceutical preparations for the digestive system, musculoskeletal system, immune stimulation, respiratory system, cold & flu symptoms, and venous circulation improvement, as well as multivitamins, antioxidants, antiseptics, disinfectants, and cosmetics, among others. Some of its brands are Triferment, Colebil, Cavit, Anghirol, Clorocalcin, and Bixtonim. Additionally, the company offers services, such as investment in research, promotion, and packaging.
1990
399
Last FY Revenue $63.9M
Last FY EBITDA $22.6M
$122M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Biofarm achieved revenue of $63.9M and an EBITDA of $22.6M.
Biofarm expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Biofarm valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $63.9M | XXX | XXX | XXX |
| Gross Profit | XXX | $53.9M | XXX | XXX | XXX |
| Gross Margin | XXX | 84% | XXX | XXX | XXX |
| EBITDA | XXX | $22.6M | XXX | XXX | XXX |
| EBITDA Margin | XXX | 35% | XXX | XXX | XXX |
| EBIT | XXX | $17.4M | XXX | XXX | XXX |
| EBIT Margin | XXX | 27% | XXX | XXX | XXX |
| Net Profit | XXX | $16.6M | XXX | XXX | XXX |
| Net Margin | XXX | 26% | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Biofarm's stock price is RON 1 (or $0).
Biofarm has current market cap of RON 698M (or $155M), and EV of RON 550M (or $122M).
See Biofarm trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $122M | $155M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Biofarm has market cap of $155M and EV of $122M.
Biofarm's trades at 1.9x EV/Revenue multiple, and 5.4x EV/EBITDA.
Equity research analysts estimate Biofarm's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Biofarm's P/E ratio is not available.
See valuation multiples for Biofarm and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $155M | XXX | $155M | XXX | XXX | XXX |
| EV (current) | $122M | XXX | $122M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 1.9x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 5.4x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | 7.0x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | 9.4x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 16.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialBiofarm's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Biofarm's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Biofarm's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Biofarm and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 35% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 20% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 57% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Biofarm acquired XXX companies to date.
Last acquisition by Biofarm was XXXXXXXX, XXXXX XXXXX XXXXXX . Biofarm acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Biofarm founded? | Biofarm was founded in 1990. |
| Where is Biofarm headquartered? | Biofarm is headquartered in Romania. |
| How many employees does Biofarm have? | As of today, Biofarm has 399 employees. |
| Is Biofarm publicy listed? | Yes, Biofarm is a public company listed on BSE. |
| What is the stock symbol of Biofarm? | Biofarm trades under BIO ticker. |
| When did Biofarm go public? | Biofarm went public in 1996. |
| Who are competitors of Biofarm? | Similar companies to Biofarm include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Biofarm? | Biofarm's current market cap is $155M |
| Is Biofarm profitable? | Yes, Biofarm is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
